Insider Transactions in Q2 2024 at Deciphera Pharmaceuticals, Inc. (DCPH)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 11
2024
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
72,261
-100.0%
|
-
|
|
Jun 11
2024
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
72,029
-49.92%
|
-
|
|
Jun 11
2024
|
Matthew L Sherman EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,157
+19.14%
|
-
|
|
Jun 11
2024
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
42,478
-100.0%
|
-
|
|
Jun 11
2024
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
72,029
-62.9%
|
-
|
|
Jun 11
2024
|
Thomas Patrick Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,157
+22.98%
|
-
|
|
Jun 11
2024
|
Jama Pitman SVP, Chief Development Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
34,243
-100.0%
|
-
|
|
Jun 11
2024
|
Jama Pitman SVP, Chief Development Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
53,951
-61.17%
|
-
|
|
Jun 11
2024
|
Jama Pitman SVP, Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,163
+18.61%
|
-
|
|
Jun 11
2024
|
Dashyant Dhanak EVP & Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
184,088
-100.0%
|
-
|
|
Jun 11
2024
|
Dashyant Dhanak EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,913
+12.34%
|
-
|
|
Jun 11
2024
|
Franklin Stuart Friedman |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
10,000
-100.0%
|
-
|
|
Jun 11
2024
|
Daniel C. Martin Chief Commercial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
31,330
-100.0%
|
-
|
|
Jun 11
2024
|
Daniel C. Martin Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
43,951
-58.38%
|
-
|
|
Jun 11
2024
|
Daniel C. Martin Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,163
+21.13%
|
-
|
|
Jun 11
2024
|
Dennis Leo Walsh |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
11,000
-100.0%
|
-
|
|
Jun 11
2024
|
Steven L. Hoerter President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
72,763
-100.0%
|
-
|
|
Jun 11
2024
|
Steven L. Hoerter President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
286,075
-79.72%
|
-
|
|
Jun 11
2024
|
Steven L. Hoerter President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
286,075
+44.36%
|
-
|
|
Apr 22
2024
|
Brightstar Associates LLC > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
48,136
+0.21%
|
$0
$0.01 P/Share
|